Cost-effectiveness of hepatitis B vaccination using HEPLISAV⢠in selected adult populations compared to Engerix-B® vaccine
Keywords: Anti-HBs; antibody to hepatitis B surface antigen; ASR; age-standardized rate; FHF'; fulminant hepatic failure; HBsAg; hepatitis B surface antigen; HBV; hepatitis B virus; HCC; hepatocellular carcinoma; ICER; incremental cost-effectiveness ratio; QALY;